Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

Home
/
insight
/
details

Understanding PD-L1 Test and its Role in Cancer Immunotherapy

NextEdge Admin

05 May 2024

3 min 2 sec

IHC,Precision medicine,diagnostic,biomarker

The PD-L1 test holds significant importance in personalized cancer treatment by evaluating tumor tissue to detect the presence and quantity of the PD-L1 protein. This protein plays a pivotal role in immune regulation, inhibiting the body’s immune response by preventing T cells from targeting healthy cells. However, cancer cells with high levels of PD-L1 can exploit this mechanism to evade immune detection and destruction.

Immunotherapy medications, particularly immune checkpoint inhibitors, block the PD-L1 protein, enabling T cells to recognize and destroy cancer cells effectively. Therefore, the PD-L1 test acts as a predictive biomarker, helping clinicians identify patients likely to benefit from immunotherapy.

These immunotherapies disrupt signals from immune checkpoint proteins like PD-L1, enhancing the immune system’s ability to attack tumors. Several PD-L1 inhibitors, such as atezolizumab, durvalumab, nivolumab, and pembrolizumab, have gained FDA approval for various clinical indications and are under evaluation for different malignancies.

The FDA categorizes PD-L1 immunohistochemistry (IHC) tests into companion diagnostic tests and complementary or codiagnostic tests. Companion diagnostic tests are essential for the safe and effective use of a drug, while complementary tests aid in treatment selection but are not obligatory for drug use.

The test is especially relevant for cancers like non-small cell lung cancer, melanoma, and bladder cancer, where immunotherapy has shown promise. It involves obtaining a tumor tissue sample during surgery or biopsy, the method of which varies based on cancer type and location.

Interpreting PD-L1 test results involves assessing whether the tumor has sufficient PD-L1 levels for immunotherapy effectiveness. A positive result suggests potential immunotherapy benefits, while a negative result prompts exploration of alternative treatments. Additional tests may be conducted to further inform treatment decisions.

PD-L1 test is a critical component of personalized cancer care, guiding treatment approaches by identifying patients likely to respond favorably to immunotherapy based on PD-L1 expression levels in their tumors.